Ronny Allan
Peptide Receptor Radionuclide Therapy (PRRT) has been around for a while and doctors are learning all the time about the most likely candidates. Selection of candidates and predictions on who will benefit most are still not an exact science (….and possibly never will be). Neuroendocrine Neoplasms are a heterogenous grouping of cancers, and heterogeneity also includes (but is not limited to) age, stage, gender, functional/non-functional, and pre-existing condition constraints. All of this complicates the task of therapeutic decision-making and sequencing.
The attached cohort study aims to bound the issue and describe a method of allocating a Clinical Score (CS) to assist doctors and patients in their decision-making. According to the lead author, the CS is the initial prognostic score to help NET patients anticipate expected benefit from PRRT and is ready for use in the clinic (although the actual document does suggest it requires prospective confirmation from ongoing clinical trials).
This is progress.
This cohort study has found the Clinical Score (CS) to be the first validated clinical metric, to our knowledge, which can estimate the anticipated benefit from 177Lu-dotatate for individual patients. Our study findings suggest that using 177Lu-dotatate when patients are less pretreated and possess a lower degree of metastatic involvement may optimize treatment outcomes; this notion, however, requires prospective confirmation from ongoing clinical trials. Click on the heading below to read.
Further reading:
Click on the photo to read:
I wrote about another paper from Italy which looks at the issues of selecting patients and evaluating responses to PRRT – click on the picture below to read. 
Top 10 Posts & Pages in the last 48 hours (auto updates)
Thanks for reading.
I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!
I found this information so helpfu!
Just in time. Thanks Ronny.
Good morning Ronny, I read this study last night and intend to read again today to better comprehend the parameters of the qualifications. Makes me feel good to read your article this morning and realize I am getting better at reading and comprehending these medical terms. Love the graphic with the blue background….. it helps! Thx. Anne